US 10,117,920 B2 · Combination of vaccination and inhibition of the PD-1 pathway

Abstract

The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine.

Claims12

Dependent claims

A method of treating a subject having a cancer or a tumor disease, the method comprising administering to the subject an effective amount of:

(i) an immunogenic composition comprising at least one mRNA comprising at least one open reading frame (ORF) encoding at least one tumor antigen, wherein the RNA is codon optimized for human codon usage, wherein the at least one mRNA comprises an increased G/C content relative to a wild-type RNA encoding the antigen;
and
(ii) a PD-1 pathway inhibitor, wherein the PD-1 pathway inhibitor is an antagonistic antibody directed against PD-L1.

Dependencies are inferred from the claim text.

Combination of vaccination and inhibition of the PD-1 pathway

Life of this patent

Combination of vaccination and inhibition of the PD-1 pathway

Life of this patent

Abstract

Claims12